Haloperidol

Uses your system voice; voice and rate in settings.

Snapshot

≈ 5 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Haloperidol, sold under the brand name Haldol among others, is a typical antipsychotic medication. Haloperidol is used in the treatment of schizophrenia, tics in Tourette syndrome, mania in bipolar disorder, delirium, agitation, acute psychosis, and hallucinations from alcohol withdrawal. It may be used by mouth or injection into a muscle or a vein.

Haloperidol typically works within 30 to 60 minutes. A long-acting formulation may be used as an injection every four weeks for people with schizophrenia or related illnesses, who either forget or refuse to take the medication by mouth. Haloperidol may result in movement disorders such as tardive dyskinesia, and akathisia, both of which may be permanent.

Neuroleptic malignant syndrome and QT interval prolongation may occur, the latter particularly with IV administration. In older people with psychosis due to dementia it results in an increased risk of death. When taken during pregnancy it may result in problems in the infant.

It should not be used by people with Parkinson's disease. Haloperidol was discovered in 1958 by the team of Paul Janssen, prepared as part of a structure-activity relationship investigation into analogs of pethidine (meperidine). It is on the World Health Organization's List of Essential Medicines.

It is the most commonly used typical antipsychotic.…

Haloperidol, sold under the brand name Haldol among others, is a typical antipsychotic medication. Haloperidol is used in the treatment of schizophrenia, tics in Tourette syndrome, mania in bipolar disorder, delirium, agitation, acute psychosis, and hallucinations from alcohol withdrawal. It may be used by mouth or injection into a muscle or a vein.

Haloperidol typically works within 30 to 60 minutes. A long-acting formulation may be used as an injection every four weeks for people with schizophrenia or related illnesses, who either forget or refuse to take the medication by mouth. Haloperidol may result in movement disorders such as tardive dyskinesia, and akathisia, both of which may be permanent.

Neuroleptic malignant syndrome and QT interval prolongation may occur, the latter particularly with IV administration. In older people with psychosis due to dementia it results in an increased risk of death. When taken during pregnancy it may result in problems in the infant.

It should not be used by people with Parkinson's disease. Haloperidol was discovered in 1958 by the team of Paul Janssen, prepared as part of a structure-activity relationship investigation into analogs of pethidine (meperidine). It is on the World Health Organization's List of Essential Medicines.

It is the most commonly used typical antipsychotic. In 2020, it was the 303rd most commonly prescribed medication in the United States, with more than 1 million prescriptions.

Discontinuation

The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. Other symptoms may include restlessness, increased sweating, and trouble sleeping.

Less commonly there may be a feeling of the world spinning, numbness, or muscle pains. Symptoms generally resolve after a short period of time. There is tentative evidence that discontinuation of antipsychotics can result in psychosis.

It may also result in reoccurrence of the condition that is being treated. Rarely tardive dyskinesia can occur when the medication is stopped. Haloperidol is a typical butyrophenone-type antipsychotic that exhibits high-affinity dopamine D 2 receptor antagonism and slow receptor dissociation kinetics.

It has effects similar to the phenothiazines. The drug binds preferentially to D 2 and α 1 receptors at low dose (ED 50 = 0.13 and 0.42 mg/kg, respectively), and 5-HT 2 receptors at a higher dose (ED 50 = 2.6 mg/kg).

Given that antagonism of D 2 receptors is more beneficial on the positive symptoms of schizophrenia and antagonism of 5-HT 2 receptors on the negative symptoms, this characteristic underlies haloperidol's greater effect on delusions, hallucinations and other manifestations of psychosis. Haloperidol's negligible affinity for histamine H 1 receptors and muscarinic M 1 acetylcholine receptors yields an antipsychotic with a lower incidence of sedation, weight gain, and orthostatic hypotension though having higher rates of treatment emergent extrapyramidal symptoms.

Cost

Haloperidol is relatively inexpensive, being up to 100 fold less expensive than newer antipsychotics.

Research

Haloperidol was under investigation for the treatment of depression. It was employed as a short-term low-dose dopamine receptor antagonist to upregulate dopamine receptors and produce receptor supersensitivity followed by drug withdrawal as a means of treating depression.

Veterinary use

Haloperidol is also used on many different kinds of animals for nonselective tranquilization and diminishing behavioral arousal, in veterinary and other settings including captivity management.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1368777994 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

27 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.